Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients

• Vitamin D reduces in vitro Th1 and Th17-related cytokine production in MS patients.
• The percentage of IL-17+ IFN-γ+ T cells was related with severity of MS.
• Vitamin D reduces in vitro the proportion of IL-17+ IFN-γ+ T cells in MS patients.
• Vitamin D elevates in vitro the percentage of dual IL-10- and IL-17-producing T cells in MS.

Vitamin D deficiency is an environmental risk factor for MS, a Th17 cell-mediated autoimmune disease that results in demyelination in the CNS. Therefore, we aimed to evaluate the ability of in vitro 1,25(OH)2D in modulating different Th17 cell subsets in MS patients in remission phase. In the present study, the production of Th17-related cytokines (IL-1β, IL-6, IL-17, IL-22), as well as GM-CSF, was significantly higher in cell cultures from MS patients than in healthy subjects (HS). The 1,25(OH)2D reduced all pro-inflammatory cytokines essayed, mainly those released from HS cell cultures. The proportion of both IL-17+ IFN-γ+ (CD4+ and CD8+) T cells and IL-17+ IFN-γ− CD8+ T cells was positively related with neurological disorders, determined by EDSS score. The addition of 1,25(OH)2D reduced not only these pathogenic T cell subsets but elevated the percentage of IL-10-secreting conventional (FoxP3+ CD25+ CD127− CD4+) and non-conventional (IL-17+) regulatory-like T cells. Taken together, the results indicate that the active form of vitamin D should benefit MS patients by attenuating the percentage of pathogenic T cells. This effect could be direct and/or indirect, by enhancing classical and non-classical regulatory T cells.

Figure optionsDownload high-quality image (108 K)Download as PowerPoint slide